Abstract
RUNX3, a runt-related transcription factor, has a crucial role in dorsal root ganglion neurogenesis. Recent studies have suggested that RUNX3 acts as a tumor suppressor in stomach, colon and breast cancer. However, the biological role of RUNX3 in neuroblastoma remains elusive. Here we report that high levels of RUNX3 expression contribute to the favorable outcome in patients with neuroblastoma, whereas low levels of RUNX3 expression result in poor outcome. Array-based analysis suggested that the allelic loss at chromosome 1p36 is one of the reasons why expression of RUNX3 is downregulated in advanced neuroblastomas. Interestingly, the several patients survived from neuroblastoma with both high mRNA expressions of MYCN and RUNX3, suggesting that RUNX3 high expression might overcome the aggressive behavior of MYCN. Exogenous expression of RUNX3 strongly inhibits cell proliferation and migration in neuroblastoma cell lines. Furthermore, RUNX3 reduces the stability of MYCN protein in MYCN-amplified neuroblastoma cell lines, and this RUNX3-mediated MYCN degradation may depend on the physical interaction between RUNX3 and MYCN. Thus, our findings provide a tumor-suppressing mechanism by which RUNX3 inhibits the MYCN activity in neuroblastoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Park JR, Eggert A, Caron H . Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010; 24: 65–86.
Nakagawara A . Neural crest development and neuroblastoma: the genetic and biological link. Prog Brain Res 2004; 146: 233–242.
Cotterill SJ, Pearson AD, Pritchard J, Foot AB, Roald B, Kohler JA et al. Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group ‘Survey’ 1982-1992. Eur J Cancer 2000; 36: 901–908.
Maris JM, Hogarty MD, Bagatell R, Cohn SL . Neuroblastoma. Lancet 2007; 369: 2106–2120.
Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A et al. Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell 2005; 7: 337–350.
Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res 2004; 10: 4–12.
Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985; 313: 1111–1116.
Suenaga Y, Kaneko Y, Matsumoto D, Hossain MS, Ozaki T, Nakagawara A . Positive auto-regulation of MYCN in human neuroblastoma. Biochem Biophys Res Commun 2009; 390: 21–26.
Maris JM, Weiss MJ, Guo C, Gerbing RB, Stram DO, White PS et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children’s Cancer Group study. J Clin Oncol 2000; 18: 1888–1899.
White PS, Maris JM, Beltinger C, Sulman E, Marshall HN, Fujimori M et al. A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. Proc Natl Acad Sci USA 1995; 92: 5520–5524.
Ohira M, Kageyama H, Mihara M, Furuta S, Machida T, Shishikura T et al. Identification and characterization of a 500-kb homozygously deleted region at 1p36.2-p36.3 in a neuroblastoma cell line. Oncogene 2000; 19: 4302–4307.
Bangsow C, Rubins N, Glusman G, Bernstein Y, Negreanu V, Goldenberg D et al. The RUNX3 gene–sequence, structure and regulated expression. Gene 2001; 279: 221–232.
Levanon D, Groner Y . Structure and regulated expression of mammalian RUNX genes. Oncogene 2004; 23: 4211–4219.
Chuang LS, Ito Y . RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene 2010; 29: 2605–2615.
Huang B, Qu Z, Ong CW, Tsang YH, Xiao G, Shapiro D et al. RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor alpha. Oncogene 2012; 31: 527–534.
Lee CW, Chuang LS, Kimura S, Lai SK, Ong CW, Yan B et al. RUNX3 functions as an oncogene in ovarian cancer. Gynecol Oncol 2011; 122: 410–417.
Lin FC, Liu YP, Lai CH, Shan YS, Cheng HC, Hsu PI et al. RUNX3-mediated transcriptional inhibition of Akt suppresses tumorigenesis of human gastric cancer cells. Oncogene 2012; 31: 4302–4316.
Yamada C, Ozaki T, Ando K, Suenaga Y, Inoue K, Ito Y et al. RUNX3 modulates DNA damage-mediated phosphorylation of tumor suppressor p53 at Ser-15 and acts as a co-activator for p53. J Biol Chem 2010; 285: 16693–16703.
Inoue K, Ito K, Osato M, Lee B, Bae SC, Ito Y . The transcription factor Runx3 represses the neurotrophin receptor TrkB during lineage commitment of dorsal root ganglion neurons. J Biol Chem 2007; 282: 24175–24184.
Inoue K, Shiga T, Ito Y . Runx transcription factors in neuronal development. Neural Dev 2008; 3: 20.
Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM . Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994; 14: 759–767.
Nakagawara A . Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 2001; 169: 107–114.
Inoue K, Ito Y . Neuroblastoma cell proliferation is sensitive to changes in levels of RUNX1 and RUNX3 protein. Gene 2011; 487: 151–155.
Ohira M, Morohashi A, Inuzuka H, Shishikura T, Kawamoto T, Kageyama H et al. Expression profiling and characterization of 4200 genes cloned from primary neuroblastomas: identification of 305 genes differentially expressed between favorable and unfavorable subsets. Oncogene 2003; 22: 5525–5536.
Nakagawara A, Arima M, Azar CG, Scavarda NJ, Brodeur GM . Inverse relationship between trk expression and N-myc amplification in human neuroblastomas. Cancer Res 1992; 52: 1364–1368.
Nakagawara A . Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities. Hum Cell 1998; 11: 115–124.
Akter J, Takatori A, Hossain MS, Ozaki T, Nakazawa A, Ohira M et al. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma. Clin Cancer Res 2011; 17: 6681–6692.
Westermann F, Schwab M . Genetic parameters of neuroblastomas. Cancer Lett 2002; 184: 127–147.
Chi XZ, Yang JO, Lee KY, Ito K, Sakakura C, Li QL et al. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol 2005; 25: 8097–8107.
Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002; 109: 113–124.
Gustafson WC, Weiss WA . Myc proteins as therapeutic targets. Oncogene 2010; 29: 1249–1259.
Otto T, Horn S, Brockmann M, Eilers U, Schuttrumpf L, Popov N et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009; 15: 67–78.
Salghetti SE, Kim SY, Tansey WP . Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J 1999; 18: 717–726.
Fredlund E, Ringner M, Maris JM, Pahlman S . High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastoma. Proc Natl Acad Sci USA 2008; 105: 14094–14099.
Chen L, Iraci N, Gherardi S, Gamble LD, Wood KM, Perini G et al. p53 is a direct transcriptional target of MYCN in neuroblastoma. Cancer Res 2008; 70: 1377–1388.
Lasorella A, Noseda M, Beyna M, Yokota Y, Iavarone A . Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins. Nature 2000; 407: 592–598.
Slack A, Chen Z, Tonelli R, Pule M, Hunt L, Pession A et al. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc Natl Acad Sci USA 2005; 102: 731–736.
Guo WH, Weng LQ, Ito K, Chen LF, Nakanishi H, Tatematsu M et al. Inhibition of growth of mouse gastric cancer cells by Runx3, a novel tumor suppressor. Oncogene 2002; 21: 8351–8355.
Yano T, Ito K, Fukamachi H, Chi XZ, Wee HJ, Inoue K et al. The RUNX3 tumor suppressor upregulates Bim in gastric epithelial cells undergoing transforming growth factor beta-induced apoptosis. Mol Cell Biol 2006; 26: 4474–4488.
Sjostrom SK, Finn G, Hahn WC, Rowitch DH, Kenney AM . The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev Cell 2005; 9: 327–338.
Tomioka N, Oba S, Ohira M, Misra A, Fridlyand J, Ishii S et al. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. Oncogene 2008; 27: 441–449.
Takenobu H, Shimozato O, Nakamura T, Ochiai H, Yamaguchi Y, Ohira M et al. CD133 suppresses neuroblastoma cell differentiation via signal pathway modification. Oncogene 30: 97–105.
Acknowledgements
This work was supported in part by a Grant-in-Aid from the Ministry of Health, Labour and Welfare for Third Term Comprehensive Control Research for Cancer, JSPS KAKENHI (Grant number 24249061) and a Grant from Takeda Science Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Yu, F., Gao, W., Yokochi, T. et al. RUNX3 interacts with MYCN and facilitates protein degradation in neuroblastoma. Oncogene 33, 2601–2609 (2014). https://doi.org/10.1038/onc.2013.221
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2013.221
Keywords
This article is cited by
-
RUNX3 inactivates oncogenic MYC through disruption of MYC/MAX complex and subsequent recruitment of GSK3β-FBXW7 cascade
Communications Biology (2023)